CRISPR-Edited cells target devastating autoimmune diseases in groundbreaking trial
NCT ID NCT06925542
Summary
This early-stage study is testing whether genetically modified immune cells can help control severe autoimmune diseases that haven't responded to standard treatments. Researchers are using CRISPR gene editing to create 'off-the-shelf' immune cells from healthy donors that target a specific protein involved in these diseases. The study will first check if the treatment is safe and look for early signs that it might reduce disease activity in adults with lupus, scleroderma, or inflammatory muscle diseases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGSt Louis, Missouri, 63130, United States
-
Research Site 2
RECRUITINGChicago, Illinois, 63110, United States
-
Research Site 3
RECRUITINGHanover, 30625, Germany
-
Research Site 4
RECRUITINGRedwood City, California, 94063, United States
-
Research Site 5
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Research Site 6
RECRUITINGBoston, Massachusetts, 02118, United States
-
Research Site 7
NOT_YET_RECRUITINGAugsburg, 86156, Germany
-
Research Site 8
RECRUITINGIowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.